Ginsenoside Rb1 Alleviated the AKI to CKD Transition by Targeting VEGFR2
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70732 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Keying Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, First Medical Center of Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research C…. Hauptthemen laut MEDLINE: Ginsenosides, Acute Kidney Injury, Vascular Endothelial Growth Factor Receptor-2, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Clinical Pharmacy Research Project of Beijing Pharmaceutical Association.
Abstract (Originalsprache)
The decrease of peritubular capillaries, a pathological feature of acute kidney injury (AKI), is a critical part that promotes the transition of AKI to chronic kidney disease (CKD). Ginsenoside Rb1 (Rb1) has various pharmacological effects on multiple systemic diseases. However, whether Rb1 delays the transition of AKI to CKD and the mechanism are unclear. Here, we discovered that Rb1 could alleviate kidney pathological damage in mice with unilateral ischaemia/reperfusion injury (uIRI), and it enhanced kidney function, reduced renal fibrosis while increasing microvessel density. By virtual screening and molecular docking approaches, we identified vascular endothelial growth factor receptor 2 (VEGFR2) as the principal molecular target of Rb1. Furthermore, we uncovered that Rb1 activated AKT phosphorylation‐mediated angiogenesis through binding to VEGFR2, which promoted endothelial tube formation and nitric oxide (NO) release in human umbilical vein endothelial cells (HUVECs) and then relieved the endothelial dysfunction induced by hypoxia‐reoxygenation (H/R). Also, we found that Rb1 activated VEGFR2/AKT signalling in the kidney tissue of uIRI mice. Knocking down VEGFR2 or inhibiting the AKT signalling pathway can impair the proangiogenic effect of Rb1. Taken together, we demonstrated that Rb1 facilitated renal angiogenesis by activating the VEGFR2/AKT pathway of endothelial cells, thereby arresting the transition from AKI to CKD, and providing a potential therapeutic strategy for AKI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, First Medical Center of Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Medical Devices a…
ORCID-Profile: Keying Zhang, Quan Hong
Förderung
- National Natural Science Foundation of China
- Clinical Pharmacy Research Project of Beijing Pharmaceutical Association
Zitieren
APA
Zhang, K., Ji, Y., Fu, Z., Wang, X., Zhang, Y., Yang, Y., Liu, R., Chen, X., Cai, G., & Hong, Q. (2025). Ginsenoside Rb1 Alleviated the AKI to CKD Transition by Targeting VEGFR2. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70732
Vancouver
Zhang K, Ji Y, Fu Z, Wang X, Zhang Y, Yang Y, et al. Ginsenoside Rb1 Alleviated the AKI to CKD Transition by Targeting VEGFR2. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70732
BibTeX
@article{Zhang2025,
author = {Zhang, Keying and Ji, Yuwei and Fu, Zhangning and Wang, Xiaochen and Zhang, Yifan and Yang, Yan and Liu, Ran and Chen, Xiangmei and Cai, Guangyan and Hong, Quan},
title = {Ginsenoside Rb1 Alleviated the AKI to CKD Transition by Targeting VEGFR2},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70732}
}
EUVIMED